

# Generate Real-World Evidence to Address Gaps in Behavioral Health



## THE URGENT NEED

There is a debilitating evidence gap that inhibits research and innovation, stemming from inherent limitations in behavioral health: complex disease etiologies, lack of quantifiable biomarkers, and institutional silos.

## OUR SOLUTION

NeuroBlu is a data and analytics platform that enables uniquely powerful evidence generation. With the most robust behavioral health database of its kind and seamless AI-powered analytic tools, NeuroBlu gives researchers, life sciences companies, clinicians, and other industry partners the ability to generate insights like never before.

## ENRICHED REAL WORLD DATA

Leading Source for Behavioral Health Real-World Evidence

**920,000+**

patients

**20+**

years of longitudinal data

**25+**

geographically- diverse psychiatry sites

**75,000,000+**


rows of data

**49,000,000+**

clinical encounters

### Behavioral Health Conditions, including:


- Substance use disorders: **255,000+ patients**
- Major depressive disorder: **251,000+ patients**
- Bipolar disorder: **134,000+ patients**
- Attention-deficit/hyperactivity disorder: **82,000+ patients**
- Post-traumatic stress disorder: **63,000+ patients**
- Schizoaffective disorder: **34,000+ patients**
- Schizophrenia: **33,000+ patients**
- Borderline personality disorder: **19,000+ patients**
- Autism spectrum disorder: **16,000+ patients**



## INSIGHTS

Gather scientifically validated, clinically meaningful insights from real-world evidence.

- ✓ **Explore:** Delve into a rich, unique database with an easy-to-use interface designed for fast and scalable queries.
- ✓ **Analyze:** Investigate research questions and enhance care delivery with state-of-the-art analytics tools, including our proprietary NLP and AI/ML algorithms which seamlessly integrates into our solutions.
- ✓ **Discover:** Generate insights with longitudinal severity scores and NLP-derived signs and symptoms, external stressors, and side effects.



### Behavioral Health Assessments, including:

- Brief Bipolar Disorder Symptom Scale (BDSS)
- Brief Negative Symptom Assessment (BNSA)
- Clinical Global Impressions (CGI-I/CGI-S)
- Columbia-Suicide Severity Rating Scale (C-SSRS)
- Global Assessment of Functioning (GAF)
- Patient Health Questionnaire-9 (PHQ-9)
- Positive Symptom Rating Scale (PSRS)
- The Daily Living Activities-20 (DLA-20)
- The Quick Inventory of Depressive Symptomatology (QIDS)

### Pharmacological Treatments, including:

- Antidepressants
- Antipsychotics
- Anxiolytics
- Hypnotics and sedatives
- Mood stabilizers
- Psycholeptics
- Psychostimulants

## VALUE

With NeuroBlu, generate real-world evidence to drive clinical and commercial success in life sciences, and improve care delivery.

- ✓ **Research and Development:** Support clinical development and increase success of trial designs.
- ✓ **Medical Affairs:** Derive patient-specific insights and population-level trends in behavioral health using AI/ML algorithms on large sets of real-world behavioral health data.
- ✓ **Market Access and HEOR:** Evaluate comparative effectiveness of pharmacological treatments in the real world and enable value-based care.

Last updated : July 2022